Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
07 May 2008 - 10:30PM
PR Newswire (US)
ARLINGTON, Va., May 7 /PRNewswire-FirstCall/ -- Champions
Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a company
engaged in the development of advanced preclinical platforms and
tumor specific data to enhance the value of oncology drugs, today
announced that it has established an agreement with ImClone Systems
Incorporated for the preclinical evaluation of certain therapeutic
antibodies in ImClone's clinical development pipeline. As part of
the agreement, ImClone will utilize Champions Biotechnology's
Biomerk Tumorgrafts(TM) in the initial preclinical evaluation.
"Studies suggest that our Biomerk Tumorgrafts provide an
accelerated and more predictive platform for the evaluation of
oncology drugs. The platform also enables biomarker discovery that
we expect will benefit us as we facilitate partnerships between
therapeutic and diagnostic companies," said Doug Burkett, Ph.D.,
President of Champions Biotechnology, Inc. "ImClone Systems has an
impressive antibody pipeline and we are pleased to be working with
them to evaluate such promising oncology therapeutic candidates."
For more information regarding Champions Biotechnology's growing
business and recent news, please visit
http://www.championsbiotechnology.com/ . About Champions
Biotechnology, Inc. Champions Biotechnology, Inc. is engaged in the
development of advanced preclinical platforms and predictive tumor
specific data to enhance and accelerate the value of oncology
drugs. The Company's Preclinical Platform is a novel approach based
upon the implantation of primary human tumors in immune deficient
mice followed by propagation of the resulting xenografts (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. The Company believes
that these Tumorgrafts closely reflect human cancer biology and
their response to drugs is more predictive of clinical outcomes in
cancer patients. Champions Biotechnology leverages its preclinical
platform to evaluate drug candidates and to develop a portfolio of
novel therapeutic candidates through pre-clinical trials. As drugs
progress through this early stage of development, the Company plans
to sell, partner or license them to pharmaceutical and/or
biotechnology companies, as appropriate. The Company also offers
its predictive preclinical platform and tumor specific data to
physicians for personalized patient care. In the course of this
process, this permits Champions Biotechnology to evaluate oncology
drugs for companies by using models that integrate prognostic
testing with biomarker discovery. Champions Biotechnology is
dedicated to enhancing preclinical development tools, accelerating
development and valuation of oncology drugs, and advancing
personalized treatment with a goal to improve the lives of cancer
patients globally. This press release contains "forward-looking
statements" (within the meaning of the Private Securities
Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as
"believe," "may," "could," "will," "intend," "expect,"
"anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-KSB for the fiscal year ended
April 30, 2007 for a discussion of such risks, uncertainties and
other factors. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they
relate only to events as of the date on which the statements are
made, and Champions Biotechnology's future results, levels of
activity, performance or achievements may not meet these
expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to
conform these statements to actual results or to changes in
Champions Biotechnology's expectations, except as required by law.
CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE:
http://www.championsbiotechnology.com/ DATASOURCE: Champions
Biotechnology, Inc. CONTACT: James Martell of Champions
Biotechnology, +1-410-630-1313 Web site:
http://www.championsbiotechnology.com/
Copyright